Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
273.53M | 233.18M | 145.24M | 212.02M | 227.49M | 198.32M | Gross Profit |
252.27M | 225.43M | 133.79M | 204.43M | 220.71M | 192.19M | EBIT |
-223.77M | -320.63M | -376.74M | -251.56M | -139.50M | -75.38M | EBITDA |
-168.21M | -265.77M | -326.25M | -299.42M | -186.68M | -143.95M | Net Income Common Stockholders |
-226.71M | -321.55M | -111.40M | -278.48M | -180.09M | -169.43M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
322.24M | 370.70M | 566.85M | 450.25M | 552.88M | 361.59M | Total Assets |
548.80M | 594.13M | 788.91M | 672.59M | 776.63M | 607.44M | Total Debt |
400.46M | 401.58M | 404.78M | 407.49M | 261.99M | 215.34M | Net Debt |
338.57M | 343.05M | 346.61M | 345.80M | 96.23M | 130.57M | Total Liabilities |
515.98M | 535.05M | 588.10M | 629.73M | 474.52M | 396.23M | Stockholders Equity |
32.82M | 59.08M | 200.81M | 42.85M | 302.11M | 211.21M |
Cash Flow | Free Cash Flow | ||||
-175.26M | -338.69M | -322.28M | -214.85M | -38.94M | -162.59M | Operating Cash Flow |
-160.66M | -237.47M | -280.02M | -186.29M | -14.79M | -42.74M | Investing Cash Flow |
35.72M | 99.33M | 55.78M | -32.55M | -137.62M | -61.33M | Financing Cash Flow |
143.66M | 139.42M | 218.75M | 117.57M | 231.68M | 127.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $2.22B | ― | 18.68% | ― | 41.67% | 75.79% | |
63 Neutral | $1.56B | ― | -5.78% | ― | 25.50% | 64.63% | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
52 Neutral | $1.41B | ― | -422.66% | ― | 49.29% | 44.52% | |
49 Neutral | $1.94B | ― | -16.57% | ― | ― | ― | |
43 Neutral | $1.64B | ― | -23.34% | ― | ― | -14.19% | |
39 Underperform | $1.25B | ― | -39.49% | ― | ― | -20.03% |
On May 15, 2025, Travere Therapeutics held its Annual Meeting where stockholders voted on several proposals. The company elected ten directors to serve until the 2026 Annual Meeting, approved an amendment to increase shares under the 2018 Equity Incentive Plan, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and strategic planning efforts.
The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.
On May 15, 2025, Travere Therapeutics announced that the FDA accepted its supplemental New Drug Application for FILSPARI® (sparsentan) for treating focal segmental glomerulosclerosis (FSGS), with a target action date set for January 13, 2026. If approved, FILSPARI could become the first FDA-approved treatment for FSGS, a rare kidney disorder affecting over 40,000 patients in the U.S. The application is supported by the Phase 3 DUPLEX Study and Phase 2 DUET Study, which demonstrated significant benefits in reducing proteinuria and improving remission rates in FSGS patients.
The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.